In July 2013, Optinose licensed exclusive North American rights for the commercialization and further development of ONZETRA® Xsail® (sumatriptan nasal powder) to Avanir Pharmaceuticals. ONZETRA Xsail received FDA approval for the acute treatment of migraines. The Avanir License Agreement is expected to terminate on March 10, 2019. Optinose is evaluating options including seeking a new license partner.
In January 2019, we entered into a License Agreement with Inexia Limited (Inexia). Under the terms of the Inexia License Agreement, we granted Inexia an exclusive worldwide license to our EDS and other intellectual property for the use, sale, import and manufacture of products containing orexin receptor agonist and/or orexin receptor positive modulator molecule(s) as the sole active pharmaceutical ingredient(s) for the treatment, diagnosis or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation.
The license excludes the treatment of any disease or condition affecting the ear, nose or throat, or the treatment of any disease or condition associated primarily with another receptor, other than the Orexin 1 and Orexin 2 receptors. Inexia is solely responsible for all costs and activities related to its identification, development and commercialization of products under the Inexia License Agreement.
As a result of the Inexia License Agreement, we have discontinued our preclinical OPN-021 program, which combined our EDS with orexin agonist molecules for the treatment of narcolepsy and symptoms of other diseases potentially amenable to the same pharmacologic activity, such as Parkinson’s disease.
Other Partnerships and Technology Licenses
Although focused on development of its own proprietary new treatments, Optinose has allowed use of its technology by a small number of academic researchers and entered into technology licensing arrangements with carefully selected companies developing their own products that may benefit greatly from this unique type of drug delivery. If your research may benefit from the use of the unique Optinose delivery technology, please call or contact us using the link below.
Please contact us at email@example.com if your company is interested in exploring partnership opportunities for an innovative, non-oral or non-injected delivery platform for your proprietary CNS, systemic or topical nasal compounds.